Abstract
Rituximab is a treatment option to non-Hodgkin’s diffuse large B-cell lymphoma (NHDLBCL) in advanced stage and comorbility. It is known the cardiotoxicity effect of this drug, but there is no previous report describing a complete atrioventricular block (CAVB) secundary to treatment with Rituximab. We present an elderly woman treated with monotherapy with Rituximab who experienced a CAVB after administration of the fifth dose of this drug.
Similar content being viewed by others
References
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemoterapy plus rituximab compared with CHOP alone in ederly patients with diffuse large-B-cell lymphoma. New Engl J Med 346:235–242
The International Non-Hodgkin’s Lymphoma Prognostic Factor Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987
Rodriguez J, Cabanillas F, McLaughlin P et al (1992) A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the “tumor score”. Ann Oncol 3:711
Cerny T, Borisch B, Introna M et al (2002) Mechanism of action of rituximab. Anticancer Drugs 13[Suppl 2]:S3–S10
Coma-Canella I, Macias A, Varo N, Sanchez Ibarrola A (2005) Neurohormones and cytokines in heart failure. Correlation with coronary flow reserve. Rev Esp Cardiol 58:1273–1277
Tsushima K, Yamaguchi S, Furihata K et al (2001) A case of renal cell carcinoma complicated with interstitial pneumonitis, complete A-V block and pleural effusion during interferon-alpha therapy. Nihon Kokyuki Gakkai Zasshi 39:893–898
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cervera Grau, J.M., Galiana, G.E., Candela, A.B. et al. Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma. Clin Transl Oncol 10, 298–299 (2008). https://doi.org/10.1007/s12094-008-0201-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0201-1